

MEDIA STATEMENT

PHILOGEN SPA ANNOUNCES PARTICIPATION IN THE “WORLD IMMUNOTHERAPY CONGRESS 2016”, 14 – 16 NOVEMBER 2016, BASEL, SWITZERLAND

[Philogen S.p.A.](#) and its fully owned subsidiary [Philochem AG](#), announce their participation to the “[World Immunotherapy Congress 2016](#)” that will take place at the Congress Center Basel from November 14 to November 16, 2016.

The three-day congress will gather more than 50 exhibitors and more than 30 speakers. The main purpose of the congress is bridging the gap between science and business to highlight the importance of immunotherapy in the fight against cancer.

Prof. Dr. Dario Neri, Swiss Federal Institute of Technology Zurich, co-founder and Chairman of the scientific advisory board of Philogen, will give a talk with the title “Antibody-cytokine fusion proteins (immunocytokines): a novel class of biopharmaceuticals for the treatment of cancer and of chronic inflammatory conditions”. The presentation is scheduled for Monday, November 14th.

For additional news and press release topics, visit: <http://www.philogen.com/en/news/>

About the Philogen group

Philogen is a clinical-stage biotechnology company engaged in the discovery and development of novel biopharmaceutical products. Philogen’s strategy is to deliver bioactive agents, for example cytokines or drugs to the site of disease using antibodies and ligands that specifically and efficiently target stromal antigens. This technology has generated a strong proprietary pipeline of clinical-stage products and also pre-clinical compounds in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem in Zürich, Switzerland. Philogen is independently owned, and has signed agreements with several major pharmaceutical companies. For more information, please visit www.philogen.com
